R enal hypertrophy, basement membrane thickening, and extracellular matrix accumulation characterize diabetic nephropathy. 1 Several cytokines with fibrogenic potential contribute to this, particularly transforming growth factor (TGF)-␤1. 2 TGF-␤1 increases matrix synthesis, inhibits matrix degradation, upregulates adhesion molecules, and enhances chemoattraction. 3, 4 The possible importance of TGF-␤1 in diabetic nephropathy has been demonstrated in vitro by glucose-induced upregulation of this cytokine in different cell types. [5] [6] [7] [8] [9] [10] [11] [12] [13] Increased TGF-␤1 expression has also been demonstrated in diabetic animal models and human patients. 14, 15 TGF-␤ binds specific serine/threonine kinase type I and type II receptors. The receptors form heteromeric cell surface complexes with TGF-␤. 16, 17 The type II receptor determines ligand specificity, whereas the type I receptor interacts with the type II receptor and might not have a specific ligand. The type II receptor, likely in conjunction with the type I receptor, is probably required for the antiproliferative effect, whereas the type I receptor is the probable mediator of extracellular gene expression. 16, 17 High glucose upregulates TGF-␤1 receptors in vitro and in vivo. 18, 19 Hyperglycemia might mediate the effect of protein kinase C (PKC) activation. 20 -24 PKC consists of several isoforms with distinct cellular functions and different expression patterns. 25 Inoguchi and coworkers 26 observed increased PKC-␤II expression in diabetic animals and hypothesized that this isoform is responsible for the glucose-induced effects. Further evidence for this hypothesis stems from a report that a specific PKC-␤ inhibitor ameliorates hyperglycemia-induced vascular changes. 27, 28 However, PKC-␤ might not be expressed in all vascular cell types. We detected no PKC-␤ expression in endothelial cells, even though these cells respond to changes in extracellular glucose concentration. 29 In addition, we reported that high glucose increases endothelial cell permeability via PKC-␣ and that PKC-␣ is important in vascular smooth muscle cell (VSMC) differentiation. 30, 31 We now tested whether or not PKC-␣ mediates glucoserelated effects on TGF-␤1 and its receptors.
Methods
All other materials, if not stated otherwise, were purchased from Sigma. Antibodies against PKC isoforms were obtained from Transduction Laboratories; against TGF-␤1, from Promega; against TGF-␤ receptors, from Santa Cruz Biotech; and secondary Cylabeled antibodies, from Dianova. Cell culture media and supplies were purchased from Seromed.
VSMC Techniques
Rat aortic VSMCs were prepared from rat aorta and cultured as previously published. 31, 32 The phenotype of the cultured VSMCs was determined by staining the cells for ␣-actin and desmin. Antibodies for muscle-specific ␣-actin and desmin were obtained from Boehringer-Mannheim. The techniques for immunoblotting have been described. 31 The final incubation was carried out with a Cy5-or horseradish peroxidase-labeled goat anti-rabbit or antimouse antibody (Dianova) in buffer for Ͼ2 hours. After they were rinsed and washed as described earlier, the blots were analyzed on a fluorescence imager (STORM, Molecular Dynamics) or by chemiluminescence (Renaissance).
Immunocytochemistry and confocal microscopy were performed as described earlier. 31 For microscopy, the preparation was mounted with mounting medium (Aqua Polymount, Polyscience) under a glass coverslip and analyzed with a Nikon-Diaphot microscope. A confocal imaging system (Bio-Rad MRC 1024, Bio-Rad Laboratories) with a UV source and an argon/krypton laser was used. At least 30 cells from each of at least 3 independent experiments were examined under each experimental condition. For each set of experiments, identical settings for power of the light source, confocal aperture, gain, and black level were used. Two separate investigators reproduced the results. Quantification of the signal intensity of single cells was done with histogram/area functions in the available software (Lasersharp or NIH Image). The cells were outlined manually, and the mean fluorescence intensity was obtained for the delineated regions. Data are presented as relative fluorescent intensity.
Quantitative PCR
For reverse transcription-polymerase chain reaction (RT-PCR), RNA was isolated by following an established protocol (TRIZOL, Gibco Life Technology). Primers were synthesized (BioTez) for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and TGF-␤. Real-time quantitative RT-PCR was performed with a commercially available system (TaqMan, PE Biosystems). Forty cycles of PCR were performed by following the protocol instructions included in the kit, with manganese concentrations of 3 mol/L for GAPDH and 4 mol/L for TGF-␤. The primer sequences were as follows: GAPDH-F: AAGCTGGTCATCAATGGGAAAC GAPDH-R ACCCCATTTGATGTTAGCGG GAPDH-P: CATCACCATCTTCCAGGAGCGCGCGAT TGF␤1-F: TCCCAAACGTCGAGGTGAC TGF␤1-R: CCATGAGGAGCAGGAAGGG TGF␤1-P: TGGGCACCATCCATGACATGAACC Each sample was tested twice. For quantification, the target sequence was normalized in relation to the GAPDH gene.
Microinjection
Microinjection of VSMCs was carried out as described previously. 32 PKC-␣ (GIBCO) was dissolved in 20 mmol/L HEPES buffer at a concentration of 1:10. For control experiments, PKC-␣ was first heated (60°C for 10 minutes) and then dissolved in HEPES buffer (1:10). Microinjection was carried out using a microinjector (Nikon). Forty to 70 fL active or denatured PKC-␣ was injected per cell. Cells were then plated on coverslips (Cellocate, Eppendorf). To confirm the efficiency of microinjection, VSMCs were fixed 30 minutes after the procedure and stained for PKC-␣ immunoreactivity. We observed a significantly increased immunoreactivity for both native and denatured PKC-␣ after microinjection. The immunoreactivity was mostly located in the cytosolic region (data not shown).
Antisense Experiments
Phosphorothioate oligodeoxyribonucleotides (ODNs) were purchased from TIB Molbiol. We selected antisense ODNs against the 3Ј-untranslated region [as ␣ (1)] and against the AUG start codon [as ␣ (2)] derived from the rat PKC-␣ sequence (accession number X07286). 30 The antisense sequence used for PKC-␣(1) was TCT TTT GTT GAG TTT CA and for PKC-␣(2) was CAG CCA TTG TCC CCC CCA AC. The sense ODN sequence, a reverse ODN sequence, and a scrambled version were used as controls. The antisense sequence used for PKC-⑀ (accession number M18331) against the rat AUG start codon was GCC ATT GAA CAC TAC CAT. The antisense sequence used for PKC-(accession number J04532) was GAT GCT CAT GGC CTC ACA CG. Antisense oligonucleotides directed against PKC-␤1 and PKC-␤II were designed and manufactured by Biognostics. For transfection, the cells were incubated with lipofectin (10 g/mL, GIBCO) and ODN (10 mol/L) in the absence of fetal calf serum and antibiotics at 37°C for 4 hours and washed 2 times with medium, and then the medium was changed back to 10% fetal calf serum for 24 hours before the start of the experiments. We have previously shown the effective and specific downregulation of PKC isoforms with this protocol 30, 31 
Construction and Expression of Plasmids Encoding PKC-␣-GFP Fusion Protein
Details of plasmid construction can be found elsewhere. 33 Transient transfection into VSMCs was carried out with SuperFect from Qiagen. Cells were seeded on glass coverslips for one day before transfection and washed 2 times with phosphate-buffered saline without Ca 2ϩ /Mg 2ϩ . They were then incubated with SuperFect and plasmid DNA in M199 culture medium for 3 hour at 37°C and 5% CO 2 and washed 2 times with phosphate-buffered saline without Ca 2ϩ /Mg 2ϩ . After transfection, the cells were cultured at 31.5°C to obtain optimal folding of green fluorescent protein (GFP). The fluorescence of PKC-GFP was detected 24 hours after transfection. Immunofluorescence of TGF-␤ and GFP expression was analyzed by confocal microscopy with a UV/laser at 365-nm/488-nm excitation and 460-nm/525-nm barrier-filter sets, respectively. Immunofluorescence was quantified as described earlier. At least 30 cells from 3 experiments were examined.
VSMCs From PKC-␣ Gene-Disrupted Mice
PKC-␣-deficient mice were developed as described elsewhere. 34 The mouse VSMCs were isolated and subjected to the same techniques as the rat VSMCs described earlier.
Results
In resting VSMCs (5 mmol/L glucose), TGF-␤ immunoreactivity was visible in the cytosol (Figure 1 ). Exposure to high (20 mmol/L) glucose led to increased immunoreactivity in the cytosol and the perinuclear region after 6 and 12 hours. After 24 hours, no significant difference in immunoreactivity compared with resting cells was observed. The right-hand panel of Figure 1A shows the semiquantitative analysis of these experiments (Ͼ30 cells of 4 independent experiments). Figure 1B shows the Western blot analysis of TGF-␤ immunoreactivity in VSMCs after 12-hour exposure to high glucose concentrations or mannose (20 mmol/L). The middle panel shows the densitometric analysis of these experiments (nϭ4, PՅ0.05). High glucose induced a significant increase in TGF-␤1 that was independent of osmotic changes. In Figure  1C , the results for quantitative PCR (TaqMan) after 6 hours of high glucose are displayed. In Figure 2 are shown the effects of high glucose on TGF-␤-R1 expression. The upper panel shows the semiquantitative analysis of the confocal photomicrographs after 6, 12, and 24 hours of exposure. High glucose (Fig 2A) led to enhanced immunoreactivity that persisted for Ͼ24 hours (Ͼ30 cells of 4 independent experiments). TGF-␤-R1 immunoreactivity after 12-hour exposure to high glucose concentrations or mannose ( Figure 2B ) confirmed the results obtained with immunocytochemistry (nϭ4, PՅ0.05). In contrast to the effects of high glucose on TGF-␤ and TGF-␤-R1, no significant effect was observed on TGF-␤-R2 (Figure 3 ). Panel A shows the semiquantitative analysis of TGF-␤-R2 immunoreactivity in VSMCs after 6, 12, and 24 hours of high glucose exposure. TGF-␤-R2 immunoreactivity 12 hours after exposure to high glucose or mannose confirmed these results ( Figure 3B ).
We next addressed whether or not the effects of high glucose were mediated by activation of PKC. High glucose increased total cellular PKC kinase activity after 6 hours by 150% (nϭ3, PՅ0.05), whereas mannose had only a minor effect (data not shown). We used PKC inhibitors as shown in Figure 4A . The upper panel shows the semiquantitative analysis of TGF-␤1 and TGF-␤-R1/2 immunofluorescence (Ͼ30 cells of 4 independent experiments) after 6-hour exposure to high glucose concentrations without and with calphostin C (10 Ϫ8 mol/L) and staurosporine (5ϫ10 Ϫ8 mol/L). Staurosporine and calphostin C reduced the effects of 20 mmol/L glucose (6 hours) on TGF-␤ and TGF-␤-R1 significantly (nϭ4, PՅ0.05). These findings were confirmed by Western blot ( Figure 4A, lower panel) . In contrast, PKC inhibition had no significant effect on the expression of TGF-␤-R2.
In the next set of experiments, we used antisense ODNs against the PKC isoforms -␣, -␤, -⑀, and -to specifically test whether or not these isoforms were responsible for the effects of glucose on TGF-␤1 and TGF-␤-R1 expression. In addition, we used TGF-␤-R2 expression as a control for possible nonspecific and toxic effects of the ODNs on VSMCs. Protein expression was assessed by semiquantitative analysis of confocal photomicrographs (Ͼ30 cells of Ն7 independent experiments). VSMCs were transfected with antisense, scrambled, and sense ODNs 24 hours before exposure to high glucose concentrations ( Figure 4B ). Both antisense ODNs against PKC-␣ showed significant inhibition on the effects of glucose on TGF-␤1 and TGF-␤-R1 (nϭ7, PՅ0.05), whereas scrambled and sense ODNs had no effect. We also found no inhibitory effect of ODNs for PKC isoforms -␤, -⑀, and -. We found no adverse effects of ODN treatment in terms of TGF-␤-R2 expression. To support the data on PKC-␣ downregulation, we isolated VSMCs from PKC-␣-deficient and wild-type mice. High glucose induced TGF-␤1 expression in the cells of the control animals but not in the PKC-␣-deficient mice ( Figure 5 ).
To further substantiate the role of PKC-␣, we microinjected PKC-␣ protein into VSMCs directly to demonstrate that this isoform is responsible for TGF-␤1 and TGF-␤-R1 expression. Protein expression in single cells was assessed by confocal microscopy. Heat-inactivated PKC-␣ served as a control; activity of the protein was assessed by an in vitro phosphorylation assay. The results are shown in Figure 6 . PKC-␣ microinjection resulted in upregulation of TGF-␤1 ( Figure 6A ) and TGF-␤-R1 ( Figure 6B ), but no effects on TGF-␤-R2 expression were observed ( Figure 6C ). Heat-inactivated material had no effect.
We next overexpressed PKC-␣ in cultured VSMCs by transfection with a plasmid containing a PKC-␣-GFP fusion protein. 33 The transfected cells showed significantly increased PKC activity compared with controls (PϽ0.05, nϭ4), indicating that the PKC-␣-GFP fusion protein was enzymatically active. 33 TGF-␤1 and TGF-␤-R1 expression was made visible by immunocytochemistry with marina blue-labeled secondary antibodies (Molecular Probes). Figure 7 shows the effect of PKC-␣ overexpression on TGF-␤1 (A) and TGF-␤R1 (C). Cells overexpressing PKC-␣ showed increased expression of TGF-␤1 after 24 hours compared with untransfected cells. TGF-␤-R1 expression was increased to a lesser extent (4 independent experiments). As a control, we overexpressed PKC-␤II-GFP fusion protein ( Figure 7B ). Expression analysis displayed no correlation between PKC-␤ and TGF-␤1 expression. No significant alteration in the expression of both proteins was observed in the nontransfected cells ( Figures 7A-7C , right-hand panels, open circles). The righthand panels of Figure 7 show the correlation between expression of PKC-␣ (green fluorescence) and expression of TGF-␤1 and TGF-␤R-1, respectively (nϭ4, PϽ0.01). No increased TGF-␤-R2 expression in PKC-␣-overexpressing cells was observed (data not shown).
Discussion
The important finding in our study was that PKC-␣ mediated the effects of high glucose on the TGF-␤ and its receptors. We demonstrated that the effects of high glucose in vitro induce the expression of both TGF-␤1 and its receptor TGF-␤-R1, whereas no effect was seen on the TGF-␤-R2. Our experiments demonstrate that the glucose-induced TGF-␤ and TGF-␤-R1 expression are most likely mediated by PKC-␣. Microinjection experiments and specific downregulation by antisense ODNs support our hypothesis. VSMCs from PKC-␣ gene-disrupted mice showed no TGF-␤ expression. Using specific antisense approaches, we found no evidence that other PKC isoforms play a major role in glucose-induced expression of TGF-␤.
An intracellular increase in PKC-␣, by direct microinjection or overexpression, increased both TGF-␤ and TGF-␤-R1 in VSMCs. The finding of a role for PKC-␣ in glucose-induced TGF-␤ expression is supported by our observation that the glucose-induced increased permeability in cultured endothelial cells was also mediated by PKC-␣. 30 Glucose-induced activation of PKC-␣ has also been described by Ganesan et al. 35 However, PKC-␤II has been implicated in the intracellular effects of glucose-induced activation of this enzyme family. In 2 rat models of diabetes, the PKC-␤II isoform was preferentially increased in aorta and heart, whereas PKC-␣ did not change significantly. 26 An increased expression of PKC-␤II was also recently reported in cultured VSMCs. 36 Further support of a role for PKC-␤II in hyperglycemia came from a study by Ishii et al, 28 who showed that an oral inhibitor of PKC-␤ ameliorates vascular dysfunction in diabetic rats. However, most of the evidence of a role for PKC-␤ in glucose-induced cell activation stems from experiments with a selective PKC-␤ inhibitor. 37 Possibly the compound used in those studies also inhibited PKC-␣. Another explanation might be differential expression of PKC isoforms in different vascular cell types or under different culture conditions.
Our previous finding that high glucose increases permeability by PKC-␣ was obtained in endothelial cells. 30 We could not detect expression of PKC-␤ by Western blot and RT-PCR in endothelial cells. 29 Possibly, glucose influences PKC-␣ in cell types where PKC-␤ is absent. However, we have previously shown that a high glucose concentration induces translocation of both PKC-␣ and -␤ in VSMCs. 31 Hyperglycemia-related effects on PKC in different cell types might vary. In skeletal muscle from hyperglycemic animals, downregulation of PKC activity was observed, whereas in other tissues, PKC activity was increased. 38 Furthermore, Donnelly et al 39 found increased PKC-in skeletal muscle from diabetic animals. We cannot rule out the possibility that other PKC isoforms mediate the effects of high glucose and hyperglycemia in other cell types and tissues. However, in our animal experiments, we observed an increase in PKC-␣ expression. This observation is supported by increased PKC-␣ expression in myocardial tissue from diabetic animals, suggesting a role for PKC-␣ in the cellular response to hyperglycemia in the heart. 40 The increased expression and colocalization of both PKC-␣ and TGF-␤ further support the hypothesis that high extracellular glucose mediates its effects on TGF-␤ via PKC-␣.
Similar findings to those reported here have been observed in mesangial cells, adipocytes, and macrophages. 5, 9, [41] [42] [43] Glucoseinduced TGF-␤ expression might directly contribute to increased expression of TGF-␤ in the vascular wall under hyperglycemic conditions. In fact, the in vitro findings of TGF-␤ induction by high glucose concentrations are accompanied by in vivo studies demonstrating increased TGF-␤ expression during hyperglycemia in animal models of diabetes. 1 Iwano et al 44 observed Less information is available on TGF-␤ receptor protein expression. 45 We observed increased expression of both a 105-kDa and a 65-kDa TGF-␤ receptor after exposure to glucose. Ahuja et al 46 observed concomitant expression of both TGF-␤1 and its receptor protein in lymphocytes. The expression of both components in the same VSMCs suggests that hyperglycemia induces an autocrine feedback mechanism. Hyperglycemia would thereby not only induce TGF-␤, which acts on other cell types to increase matrix expression, but also enhance this effect by concomitantly causing TGF-␤ to express its own receptor. 47 Such a model implies that both TGF-␤ and its receptors are regulated by similar mechanisms, including PKCresponsive signaling pathways. However, our data also suggest that TGF-␤-R1 and TGF-␤-R2 are differentially regulated. This finding is in contrast to the report by Sharma et al, 4 who observed an increase in TGF-␤-R2 mRNA in the kidneys of diabetic animals. Because we did not assess mRNA levels for the receptors, it is possible that the processing of the 2 receptors is different. 16 The differential expression of TGF-␤ receptor proteins in our study raises the possibility that TGF-␤ exerts specific effects in hyperglycemia.
Perspective
Our findings underscore TGF-␤ and its receptors as potential therapeutic targets. Because PKC-␣ appears to mediate the extracellular stimuli that induce TGF-␤ expression, specific inhibition of the PKC-␣ isoform might diminish the adverse effects of hyperglycemia in diabetes mellitus. 
